Yesterday | CiteULike
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
RESEARCH DESIGN AND METHODS: This 28-week parallel-group study randomized 233 insulin-naive patients with HbA values>/=8.0% on>1,000 mg/day metformin alone or in combination with other OADs.
Researchers find evidence of survival gains in bone marrow disease
A recent study, published in the December issue of Mayo Clinic Proceedings , demonstrates new survival data for the blood disorder myelofibrosis.
UNC Scientists Coordinate Study to Determine Link Between Insulin Use ...
Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine , may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.
Report on the type 2 diabetes drug market in Brazil
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
Shedding Light on the Co-morbidities of Diabetes The Complications of Having Rheumatoid Arthritis and Diabetes Insulin shots vs insulin pump 11/18/09 yoli Topics: Insulin shots vs insulin pump I have been a diabetic for 10 years.
Diabetes sufferers to finally get free insulin pens
The social policy ministry is expected to rectify a long-standing, and painful issue for sufferers of diabetes.
Wellstat, Sanofi Ink $350M Deal for Phase II Insulin Sensitizer
Privately held Wellstat Therapeutics Corp. stands to gain up to $350 million, including an undisclosed up-front payment, in exchange for global rights to its Type II diabetes oral insulin sensitizer PN2034 and related compounds in a development and commercialization deal with Sanofi-Aventis Group SA, which sought the licensing agreement to beef up ...
Sanofi-Aventis and Wellstat Therapeutics Enter into an Exclusive...
Paris, October 21, 2009 Sanofi-aventis and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes.
Data Analysis Reinforces the Safety Profile of Levemir
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes , demonstrated that the Novo Nordisk long-acting insulin Levemir was not associated with any increase in the incidence of cancer when compared to human insulin .
Biosimilar Insulins And Insulin Analogues Stand To Erode $6.1B...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1B in brand sales in the U.S. and Europe by 2018, saving healthcare systems $3.8B in the process.
Drug coverage based on cost, effectiveness works: study
Provincial drug plans often follow the coverage recommendations of Canada's Common Drug Review board.
Novo Nordisk reports study data for NovoMix 30 in Type 2 diabetes patients
Findings demonstrate that Type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix 30 achieve a significantly greater HbA reduction compared to patients starting with a daily injection of insulin glargine.
Superior Efficacy-dose Ratio for Lantus Over detemir
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin detemir.
Levemir Does Not Increase Risk of Cancer: Studies
Novo Nordisk's Levemir was not associated in any increase in incidence of cancer when compared with human insulin in studies including some 9,000 patients, according to a new analysis released on Thursday.
Report: Doctors to examine possible link between diabetes, cancer
NEW YORK Possible links between a popular brand of insulin and cancer have prompted doctors to investigate, according to published reports.
Cancer Alert Explored as Sanofi, Novo Diabetes Drugs Scrutinized in Vienna
Doctors will try to unravel possible ties between diabetes treatments and cancer this week after studies indicated that medicines used by millions of people may leave some vulnerable to tumors.
Sanofi-Aventis To Launch Insulin Research Program
French drugmaker Sanofi-Aventis said Tuesday that it is planning to undertake methodologically robust research that will contribute to the scientific resolution of the debate over insulin safety, including insulin analogs and its Lantus drug.
Effects of Initiating Insulin and Metformin on Glycemic Control and...
Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial Export JAMA , Vol.
Diabetes Mine - the all things diabet...
"What a wonderful book! Diabetes can feel confusing and overwhelming, but it doesn't have to be a ' especially thanks to books like this." a ' Dr.
No evidence for insulin glargine cancer risk
Thursday, 24 September 2009, 11:29 am Press Release: Ministry of Health No conclusive evidence linking insulin glargine to higher cancer risk Medicines regulatory authorities in New Zealand have found no conclusive evidence that the use of insulin glargine is associated with increased risk of developing cancer, saying findings of recent studies may ...
Also on Topix